menu
    • menu
    [{"orgOrder":0,"company":"SQ Innovation","sponsor":"SQ Innovation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"SQ Innovation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SQ Innovation \/ SQ Innovation","highestDevelopmentStatusID":"11","companyTruncated":"SQ Innovation \/ SQ Innovation"},{"orgOrder":0,"company":"SQ Innovation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"SQ Innovation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SQ Innovation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"SQ Innovation \/ Undisclosed"},{"orgOrder":0,"company":"SQ Innovation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"SQ Innovation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SQ Innovation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"SQ Innovation \/ Undisclosed"},{"orgOrder":0,"company":"SQ Innovation","sponsor":"Accel Clinical Services","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"SQ Innovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SQ Innovation \/ Accel Clinical Services","highestDevelopmentStatusID":"7","companyTruncated":"SQ Innovation \/ Accel Clinical Services"},{"orgOrder":0,"company":"SQ Innovation","sponsor":"EB Medical Research | Quartesian","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"G3P-01","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"SQ Innovation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SQ Innovation \/ EB Medical Research | Quartesian","highestDevelopmentStatusID":"1","companyTruncated":"SQ Innovation \/ EB Medical Research | Quartesian"},{"orgOrder":0,"company":"SQ Innovation","sponsor":"University of Glasgow | NHS Greater Glasgow and Clyde","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SQIN-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"SQ Innovation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SQ Innovation \/ University of Glasgow | NHS Greater Glasgow and Clyde","highestDevelopmentStatusID":"6","companyTruncated":"SQ Innovation \/ University of Glasgow | NHS Greater Glasgow and Clyde"},{"orgOrder":0,"company":"SQ Innovation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"SQ Innovation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SQ Innovation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"SQ Innovation \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by SQ Innovation

    Menu

    SQ Innovation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SQ Innovation

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            SQ Innovation

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furosemide

                            Therapeutic Area : Nephrology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart F...

                            Details : Lasix ONYU (Furosemide) is a small molecule drug candidate, which is currently being evaluated in Approved FDF clinical studies for the treatment of Edema.

                            Product Name : Lasix ONYU

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 09, 2025

                            Lead Product(s) : Furosemide

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SQ Innovation

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            SQ Innovation

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furosemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Recipient : University of Florida

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Gator SCALES-WHF: Subcutaneous Lasix to Eliminate Symptoms of Worsening HF

                            Details : Furosemide is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 20, 2025

                            Lead Product(s) : Furosemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Recipient : University of Florida

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SQ Innovation

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            SQ Innovation

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furosemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Gerresheimer: FDA grants Tentative Approval of SQ Innovation's Lasix® ONYU*

                            Details : Lasix ONYU (furosemide) is a sodium-(potassium)-chloride cotransporter 2 inhibbitor, indicated in adults & pediatric patients for the treatment of edema associated with heart failure.

                            Product Name : Lasix ONYU

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 16, 2024

                            Lead Product(s) : Furosemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SQ Innovation

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            SQ Innovation

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furosemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New Device and Drug Combination Could Revolutionize Heart Failure Treatment

                            Details : Lasix ONYU (furosemide) is a sodium-(potassium)-chloride cotransporter 2 inhibbitor, being evaluated in adults & pediatric patients for the treatment of edema associated with heart failure.

                            Product Name : Lasix ONYU

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 27, 2023

                            Lead Product(s) : Furosemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            SQ Innovation

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            SQ Innovation

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : G3P-01

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : EB Medical Research | Quartesian

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Safety/Tolerance Phase, Ascending Single Dose Study to Evaluate the Safety and Tolerability of G3P-01, a Foo...

                            Details : G3P-01 is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Gastrointestinal Diseases.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            March 25, 2022

                            Lead Product(s) : G3P-01

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : EB Medical Research | Quartesian

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            SQ Innovation

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            SQ Innovation

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SQIN-01

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : University of Glasgow | NHS Greater Glasgow and Clyde

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess Safety and Efficacy of a Novel Patch Infusor Device and Novel SUBCUTaneous Furosemide Formul...

                            Details : SQIN-01 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 15, 2021

                            Lead Product(s) : SQIN-01

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : University of Glasgow | NHS Greater Glasgow and Clyde

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            SQ Innovation

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            SQ Innovation

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furosemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Accel Clinical Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered...

                            Details : Furosemide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 12, 2020

                            Lead Product(s) : Furosemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Accel Clinical Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth